Being in the ASX 300 is great for a lot of speculative stocks......

Being in the ASX 300 is great for a lot of speculative stocks... the appetite of the investors create a nice environment for valuations to be driven by sentiment and stocks can perform quite well with very little revenue/cash flow and scrutiny... but now that we are in the ASX 200, it really is a double edged sword.

Yes, a lot more eyes will be on us... but with that comes a lot more scrutiny... and a very different investor base/appetite. Valuations are more likely to be challenged and risk-plays may be avoided. Where ASX 300 investors may be more likely to accept high risk / high return companies... the ASX 200 investor is more likely to look for a company that is cash flow positive, has a high dividend yield, franked dividends, predictable growth and a management team that has proven itself.

The fact we are in the ASX 200 does not guarantee success.. but it does put us on a very visible platform in the most critical 3-6 months of our corporate life. If any of our trials fail (three FDA phase 3 trials due to read-out at any time), the sell-off will be swift. But if we succeed the coverage, recognition, and upside will be amplified.

So we are the new kids on the block... and you know what, we are very different. We just entered an elite group of companies and we are not wearing a suit, instead we are wearing a lab coat... we don't have much revenue, but we have a damn impressive IP portfolio, damn we don't even have many products to sell, but our near term pipeline is as exciting as anything you will see on a listed stock exchange in the world.

First day on the ASX 200 and we topped a list already... top decline of 10.63% in all ASX 200 companies... what a first impression!

But having said all that... I am not one bit phased about what we are facing. We may get bullied.. knocked around a bit... our new peers may not respect or understand what we do... but we are not here to make friends... we are here to save lives and make a lot of money doing it. Silviu doesn't look at MSB with Australian companies as peers... our market is the rest of the world, and in particular the US market. Health care companies in the US with much less potential and insignificant near-term pipelines relative to MSB's are valued significantly more than us.

TIme for this new kid to show the ASX what it can do... and you know who else wears a lab coat? The largest ASX listed company in Australia.. big brother.. CSL.